Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (401-410 of 688) with videos related to

Pageof 69
Sort By:
Kidney Diseases (Basel, Switzerland)|June 24, 2025
Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisTakashi Wada, Stefan D Anker, Zhihong Liu, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2022
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 DiabetesLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
European Heart Journal|June 16, 2026
Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failureVeena S Rao, Juan B Ivey-Miranda, Zachary L Cox, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD TrialRajiv Agarwal, Amer Joseph, Stefan D Anker, et al.
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Kidney International Reports|February 3, 2026
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKDAjay K Singh, Stefan D Anker, Bertram Pitt, et al.
The American Journal of Medicine|August 5, 2018
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart RatePhillip H Lam, Neha Gupta, Daniel J Dooley, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
Clinical Trials (London, England)|February 16, 2012
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) StudyFrederick L Brancati, Mary Evans, Curt D Furberg, et al.
Pageof 69

Showing results (401-410 of 688) with videos related to

Sort By:
Pageof 69
Kidney Diseases (Basel, Switzerland)|June 24, 2025
Efficacy and Safety of Finerenone in Asian Patients with Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY AnalysisTakashi Wada, Stefan D Anker, Zhihong Liu, et al.
Hypertension (Dallas, Tex. : 1979)|October 17, 2022
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 DiabetesLuis M Ruilope, Rajiv Agarwal, Stefan D Anker, et al.
Blood Pressure|July 7, 2007
Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson, George L Bakris, Björn Dahlöf, et al.
European Heart Journal|June 16, 2026
Blood aldosterone concentrations and effects of mineralocorticoid receptor antagonists in heart failureVeena S Rao, Juan B Ivey-Miranda, Zachary L Cox, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD TrialRajiv Agarwal, Amer Joseph, Stefan D Anker, et al.
European Journal of Heart Failure|February 16, 2019
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trialJoão Pedro Ferreira, Paula Abreu, John J V McMurray, et al.
Kidney International Reports|February 3, 2026
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKDAjay K Singh, Stefan D Anker, Bertram Pitt, et al.
The American Journal of Medicine|August 5, 2018
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart RatePhillip H Lam, Neha Gupta, Daniel J Dooley, et al.
European Journal of Heart Failure|January 28, 2014
The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patientsGeorge V Moukarbel, Zi-Fan Yu, Kenneth Dickstein, et al.
Clinical Trials (London, England)|February 16, 2012
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) StudyFrederick L Brancati, Mary Evans, Curt D Furberg, et al.
Pageof 69